HIV/AIDS
FDA Approves Combination Treatment Symfi for HIV-1 Infection
Symfi contains the same triple combination ingredients found in the recently approved and launched Symfi Lo but with a 600mg dose of efavirenz vs 400mg seen in Symfi Lo.
For Those With HIV, Symptom Burden Higher in Women
Among respondents to the female survey, the burden scores were higher in women reporting amenorrhea due to natural menopause or hysterectomy (104 respondents) versus the menstruating group (118 respondents) for muscle aches/pains (P=0.05), fatigue (P=0.03), and difficulty falling asleep (P=0.04), independent of age, HIV duration, and number of HIV-associated, non-AIDS conditions.
Raltegravir Labeling Updated With Long-Term Data from Phase 3 HIV Trial
The Isentress (raltegravir) and Isentrress (raltegravir) HD label was recently updated to include Week 96 data from the Phase 3 trial (ONCEMRK).
High Adherence to HIV Preventative Vaginal Ring Seen in Study
As of October 2017 — the cut off date for interim analysis — 89% of the rings returned had residual dapivirine levels consistent with some use in the prior month.
Trogarzo Approved to Treat Multidrug Resistant HIV-1 Infection
The safety and efficacy of Trogarzo were evaluated in a clinical trial of 40 heavily treatment-experienced patients with MDR HIV-1 who continued to have high levels of virus (HIV-RNA) in their blood despite being on antiretroviral drugs.
Biktarvy Found to Be Non-Inferior to Abacavir-Containing Regimen in Phase 3 Study
Biktarvy is indicated as a complete regimen for the treatment of HIV-1 in adults who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50c/mL) on a stable antiretroviral regimen for at least 3 months, with no history of treatment failure and no known substitutions associated with resistance to the individual components of Biktarvy.
Symfi Lo, Cimduo Will Be Available Soon for HIV Treatment
Symfi Lo will be available in the coming weeks whereas Cimduo is expected in the second quarter of 2018.
Unexpected Toxicities Identified With Concomitant HIV, Tuberculosis Tx Use
The study had to be cut short when 2 of 4 subjects developed serious toxicities following the third isoniazid-rifapentine dose.
FDA Approves Biktarvy to Treat HIV-1 Infection in Adults
Biktarvy combines bictegravir, an integrase strand transfer inhibitor (INSTI), and emtricitabine (FTC) and tenofovir alafenamide (TAF), two nucleoside reverse transcriptase inhibitors (NRTIs).
Three-Drug Combo Symfi Lo Approved for the Treatment of HIV
Symfi Lo combines efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor (NNRTI), and lamivudine (3TC) and tenofovir disoproxil fumarate (TDF), both nucleo(t)side reverse transcriptase inhibitors.
Edurant Dosing Recommendations Updated for Pregnant HIV Patients
Lower exposures of rilpivirine were observed during pregnancy, therefore viral load should be monitored closely.
Prezcobix Labeling Updated With New Drug Interactions
Prezcobix, a combination of an HIV-1 protease inhibitor and a CYP3A inhibitor, is indicated to treat HIV-1 infection in adults.
Neurodevelopmental Differences Examined in HIV+, HIV-Exposed Children
The researchers found that HIV+ and HEU children had lower cognitive and motor scores than their HUU peers within the meta-analysis.
CDC Examines HIV Testing Rates, Reasons For Having Never Been Tested
Overall, 38.8% of women and 53.8% of men had never been tested in 2011 to 2015.
HIV Privacy Breach Lawsuit Reaches Settlement
The privacy breach occurred in July 2017, when letters outlining that beneficiaries could now pick up their medications in person were sent in envelopes with large address windows which made private health information visible.
Juluca Labeling Updated to Correct Dosing Separation Information
Juluca was approved as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of Juluca.
Over one-third of U.S. HIV patients are not vaccinated against hepatitis B
One third of HIV patients in the United States remain unvaccinated against hepatitis B.
Single-Dose HIV Med May Deliver Sustained Antiretroviral Concentrations
The researchers found that the orally-administered platform delivered three antiretrovirals for up to seven days after a single administration, with week-long systemic drug levels identified.
Teva Launches Generic Reyataz Capsules
Atazanavir Sulfate is an HIV-1 protease inhibitor indicated to treat HIV-1 infection in combination with other antiretrovirals
Hepatitis B Vaccination Often Missed Among HIV Patients
More than one-third of adult HIV patients receiving medical care have not been vaccinated
Viread Generic Now Available From Teva
Tenofovir disoproxil fumarate tablets are a nucleotide analog HIV-1 reverse transcriptase inhibitor.
Antiretroviral Combination Linked to Increased CKD Risk
The risk of chronic kidney disease (CKD) may be increased in patients living with HIV receiving tenofovir (TDF) with a ritonavir-boosted protease inhibitor compared to those who receive TDF with a non-nucleosidic reverse transcriptase inhibitor (NNRTI)
Cancer Drug Linked to Drastic Depletion of HIV Reservoirs
Case report describes smoker with HIV infection receiving nivolumab for non-small-cell lung cancer
New Guidelines Issued for Managing Chronic Pain in HIV Patients
All PWLH should receive brief standardized screening for chronic pain. A biopsychosocial approach should be used; and appropriate monitoring should take place.
CDC: 7-Month Improvement in Time From HIV Infection to Diagnosis
Increase in percentage of people at increased risk for HIV who reported getting an HIV test in past year.
First Complete 2-Drug HIV Regimen Gets FDA Approval
Juluca combines dolutegravir, an HIV-1 integrase strand transfer inhibitor (INSTI), and rilpivirine, a non-nucleoside reverse transcriptase inhibitor.
Early cART, Viral Suppression May Minimize Brain Injury in HIV Patients
No significant neuropsychological decline during two-year period with combination antiretroviral therapy
In ART-Treated HIV Patients With GI Discomfort, Consider EPI Assessment
Of 100 participants, 32% had EPI (faecal elastase-1 <200 μg/g) and 20% severe EPI (faecal elastase-1 <100 μg/g).
Direct-Acting Antivirals Beneficial for HCV/HIV Co-Infected Patients
The authors write, "the advent of direct acting antiviral (DAA) agent therapies has resulted in significant improvements in treatment rates for those with co-infection."
Increasing Resistance to HIV Drugs Threatening Control Efforts
WHO has proposed 5-point plan for monitoring, combating, and preventing drug resistance